title: Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi.
abstract: OBJECTIVE
  To determine if there was any difference in the ability of physicians to predict prognosis with technetium 99m ((99m)Tc) sestamibi or (99m)Tc tetrofosmin in a large consecutive series of patients at high risk for coronary artery disease who underwent coronary angiography.
  
  
  METHODS
  This study included 1,818 consecutive patients who underwent a rest and stress single photon emission computed tomographic (SPECT) examination with either (99m)Tc sestamibi (n = 915) or (99m)Tc tetrofosmin (n = 903) and cardiac catheterization. A clinical index was generated and consisted of clinical and demographic variables. Information concerning death, cardiovascular death, and nonfatal myocardial infarction was 93% complete during the 1.5-year study period. Cox proportional hazards models were generated to help determine the incremental contribution of SPECT sum stress score (SSS) and the imaging agent variable to the clinical index.
  
  
  RESULTS
  Exercise was used for stress testing in 473 (52%) patients who received (99m)Tc tetrofosmin and 519 (57%) patients who received (99m)Tc sestamibi (P =.06). Cardiovascular death or myocardial infarction occurred in 130 patients. Resulting P values for chi(2) differences between models for the end points of (a) death from any cause, (b) cardiovascular death, and (c) cardiovascular death or myocardial infarction showed that SSS combined with clinical index was a significantly better model than adjusting for only baseline characteristics (P =.001, P <.001, P =.004, respectively). Incremental addition of either (99m)Tc tetrofosmin or (99m)Tc sestamibi to those models containing SSS and the clinical index did not show further significant improvement (P =.87, P =.88, and P =.26 for death from any cause, cardiovascular death, and cardiovascular death or myocardial infarction, respectively).
  
  
  CONCLUSIONS
  This study shows that the type of clinically available (99m)Tc-labeled myocardial perfusion agents should not affect interpretation of results for risk stratification and prognostic assessment.
authors.affiliation: Department of Medicine, Duke Clinical Research Institute and Drexel School of Medicine, Duke University Medical Center, PO Box 3949, Durham, NC 27710, USA. borge001@mc.duke.edu
authors.forename: Salvador
authors.initials: S
authors.lastname: Borges-Neto
authors.forename: Robert H
authors.initials: RH
authors.lastname: Tuttle
authors.forename: Linda K
authors.initials: LK
authors.lastname: Shaw
authors.forename: William T
authors.initials: WT
authors.lastname: Smith
authors.forename: Diwakar
authors.initials: D
authors.lastname: Jain
authors.forename: R Edward
authors.initials: RE
authors.lastname: Coleman
authors.forename: David
authors.initials: D
authors.lastname: Whellan
mesh_terms: D000241:Adenosine; D000368:Aged; D002318:Cardiovascular Diseases / Q000401:mortality; D003326:Coronary Circulation; D003327:Coronary Disease / Q000000981:diagnostic imaging*; D004176:Dipyridamole; D004280:Dobutamine; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D011379:Prognosis; D016016:Proportional Hazards Models; D018570:Risk Assessment; D017256:Technetium Tc 99m Sestamibi; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D004280:Dobutamine; C078700:technetium tc-99m tetrofosmin; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi; D000241:Adenosine